Non-profit funding sight-saving research for children

Check our Past Winners page for all past winners! ✨🌟

How the treatments work

Gene replacement, gene editing, RNA drugs, optogenetics, cell therapy, implants and small molecules, explained in plain words: what each one does inside the eye, what it needs to work, and how it gets there. The live status of every therapy lives in the pipeline, not on this page.

The approaches, one by oneWhere things stand

Two families of treatment

Every approach on this page belongs to one of two families. The difference decides who a treatment can help and what has to be known first.

Gene-specific

Fixes, replaces or silences one named gene

Who it can help
People with a confirmed change in that gene. A genetic test result is the entry ticket.
What it aims to do
Treat the cause: supply a working copy of the gene, correct the DNA, or change how the gene's message is read.
The catch
About 300 genes are involved in inherited retinal disease, so each gene needs its own program, and some genes are too large for the delivery vehicles used today.

Gene-agnostic

Works whatever the gene

Who it can help
People with any inherited retinal disease, including those whose gene was never found.
What it aims to do
Protect cells that remain, make other cells light-sensitive, replace lost cells, or feed signals to the brain electronically.
The catch
It does not repair the underlying genetic change, and each approach suits some stages of disease better than others.

The approaches, one by one

Eight ways to treat a retina that is losing its photoreceptors. The order runs from "fix the gene" to "bypass the eye".

  • Gene replacement

    Gene-specific

    A harmless virus shell (usually an adeno-associated virus, AAV) carries a working copy of the gene into retinal cells, which then make the protein they were missing. The one approved gene therapy for an inherited retinal disease works this way: voretigene neparvovec (Luxturna), for RPE65-related disease, approved in the United States in 2017.

    Needs: living target cells and a gene small enough for AAV (roughly 4.7 thousand DNA letters).

    Given: usually by injection under the retina during surgery.

  • Gene editing

    Gene-specific

    Instead of adding a gene, editing tools such as CRISPR change the DNA letters inside the cell. Because only the editing machinery travels, this can address genes too large to deliver whole. Newer forms, base and prime editing, change single letters without cutting both DNA strands.

    Needs: living cells and an exact match to the person's variant.

    Given: injection under the retina.

  • RNA therapies

    Gene-specific

    These drugs act on the gene's message (RNA) rather than the DNA. Antisense oligonucleotides can mask a splicing error so a usable protein is made; RNA interference can quiet a harmful copy of a gene. The effect fades, so they are given repeatedly.

    Needs: a specific variant the drug is designed for.

    Given: injection into the eye, repeated.

  • Optogenetics

    Gene-agnostic

    A gene for a light-sensing protein is delivered to retinal cells that normally don't sense light, such as bipolar or ganglion cells, so they can respond to light after the photoreceptors are gone. The first optogenetic therapy, MOGENRY (MCO-010) for retinitis pigmentosa with severe vision loss, had its approval application accepted by the FDA in September 2026; a decision is pending.

    Needs: surviving inner retinal cells.

    Given: injection into the eye, in the office.

  • Neuroprotection

    Gene-agnostic

    Drugs or delivered proteins that help photoreceptors survive longer, whatever is killing them: antioxidants, growth factors, or agents that calm the stress inside the cell. The aim is to slow loss rather than restore sight.

    Needs: cells that are still alive to protect.

    Given: by mouth, by injection, or from a small implant.

  • Cell therapy

    Gene-agnostic

    Replacing lost cells with new ones grown from stem cells: the retinal pigment epithelium that supports photoreceptors, or photoreceptors themselves. Getting new cells to connect to the retina's wiring is the central scientific challenge.

    Needs: a retina that can accept and connect new cells.

    Given: transplant under the retina during surgery.

  • Retinal and visual prostheses

    Gene-agnostic

    Electronic implants that turn light from a camera or the eye into electrical pulses for the remaining retinal neurons or, in research, for the visual cortex. What they give is a form of artificial vision, not natural sight.

    Needs: working nerve cells behind the implant.

    Given: surgery.

  • Small-molecule drugs

    Mostly gene-agnostic

    Conventional medicines, often taken by mouth, that change the chemistry of the retina: slowing the build-up of toxic by-products of the visual cycle, for example, or restoring light sensitivity to cells. Some are designed for one condition; a few for one gene.

    Needs: depends on the drug.

    Given: usually by mouth.

Related, and already current care: setmelanotide (Imcivree) is approved for hunger and weight in Bardet-Biedl syndrome; it treats the syndrome's obesity, not the eyes.

Where things stand

Every approach, with its therapies placed on the track by how far they have come. Built from our treatment pipeline, so it moves when the pipeline moves.

  1. In research

    • Gene replacement1 therapy

      BBS7

  2. In clinical trials

    • Gene replacement20 therapies

      RS1, RPGR

    • Optogenetics7 therapies

      ZM-02 (PsCatCh2.0), GS030 (Optogenetics)

    • Retinal and visual prostheses1 therapy

      PRIMA System (Subretinal)

    • Small-molecule drugs8 therapies

      ABCA4 (pharmacological read-through), RHO (rhodopsin corrector)

    • Neuroprotection2 therapies

      NACA (N-acetylcysteine amide), NAC (N-acetylcysteine)

    • RNA therapies4 therapies

      ABCA4 (RNA exon editing), USH2A (exon 13)

    • Cell therapy4 therapies

      OpCT-001 (iPSC photoreceptors), DSP-3077 (iPSC retinal sheets)

    • Gene editing1 therapy

      CEP290

  3. Approved care

    • Gene replacement1 therapy

      Luxturna (voretigene neparvovec-rzyl) (RPE65)

Counts and examples from the RAB treatment pipeline, as of October 2026. For information only; talk with your retina specialist. Open the full pipeline

How a treatment reaches the retina

The retina sits at the back of the eye, behind the gel that fills it. There are three ways in.

  • Under the retina (subretinal)

    A surgeon lifts a small area of the retina and places the treatment beneath it, next to the photoreceptors and the pigment layer. Done in an operating room; used for Luxturna and most gene replacement trials.

  • Into the eye (intravitreal)

    An injection into the gel of the eye, done in the office, the same route used for common retinal drugs. Used for RNA therapies, optogenetics and some newer gene therapies designed to reach the retina from the gel.

  • By mouth, or from an implant

    Pills and capsules that reach the retina through the bloodstream, and small implants that release a drug slowly over months. Used for neuroprotective and small-molecule approaches.

  • What the routes have in common

    Injected and surgical treatments go into one eye at a time and are usually studied in one eye first; every route is followed by months of monitoring. Trials spell out which eye, how often, and what is measured.

Questions to ask about any therapy or trial

Bring these to your retina specialist or to a trial's study team.

  • Is this treatment for my gene, or for any gene?
  • What does it need from my retina to work, and do I have that today?
  • How is it given, how many times, and in which eye?
  • What has it shown so far, in how many people, and over how long?
  • What are the known risks, and what would make me ineligible?
  • Who pays, and what happens after the study ends?

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice. It is not a substitute for seeking medical opinions, nor an endorsement of any treatments, research, or organizations. Trial information is sourced from ClinicalTrials.gov and public press releases. Genetic testing and clinical management should be performed by qualified healthcare professionals, including ophthalmologists and genetic counselors.

Sources

  1. U.S. Food and Drug Administration, Luxturna (voretigene neparvovec-rzyl) prescribing information and approval (December 2017).
  2. Gene-Based Therapeutics for Inherited Retinal Diseases (review, 2021; AAV packaging capacity and delivery routes).
  3. Optogenetics and targeted gene therapy for retinal diseases (review, 2024).
  4. Nanoscope Therapeutics, FDA acceptance of the Biologics License Application for MOGENRY (September 9, 2026).
  5. U.S. Food and Drug Administration, Imcivree (setmelanotide) approval for Bardet-Biedl syndrome (June 2022).
  6. RAB treatment pipeline (live data; counts and examples on this page).